Cyclin-dependent kinase inhibitors: a survey of recent patent literature
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cyclin-dependent kinase inhibitors: a survey of recent patent literature
Authors
Keywords
-
Journal
EXPERT OPINION ON THERAPEUTIC PATENTS
Volume 20, Issue 3, Pages 377-404
Publisher
Informa Healthcare
Online
2010-02-24
DOI
10.1517/13543770903524284
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A dose escalation, pharmacokinetic, and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors
- (2017) D. Mahadevan et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignancies
- (2017) G. I. Shapiro et al. JOURNAL OF CLINICAL ONCOLOGY
- You never know: Cdk inhibitors as anti-cancer drugs
- (2011) Tim Hunt CELL CYCLE
- State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy
- (2009) Sindura B. Ganapathi et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- The regulation of protein phosphorylation
- (2009) Louise N. Johnson BIOCHEMICAL SOCIETY TRANSACTIONS
- The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity
- (2009) S. Ali et al. CANCER RESEARCH
- Off-Target Decoding of a Multitarget Kinase Inhibitor by Chemical Proteomics
- (2009) Enrico Missner et al. CHEMBIOCHEM
- Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer
- (2009) W.-S. Hsieh et al. CLINICAL CANCER RESEARCH
- Gastrosplenic Fistula From Hodgkin's Lymphoma
- (2009) Carolyn D. Seib et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
- (2009) N Raje et al. LEUKEMIA
- Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines
- (2009) M. S. Squires et al. MOLECULAR CANCER THERAPEUTICS
- The rise of fragment-based drug discovery
- (2009) Christopher W. Murray et al. Nature Chemistry
- Cyclin-dependent kinase 5 activator p35 over-expression and amyloid beta synergism increase apoptosis in cultured neuronal cells
- (2009) E. Utreras et al. NEUROSCIENCE
- Identifying Tumor Cell Growth Inhibitors by Combinatorial Chemistry and Zebrafish Assays
- (2009) Jing Xiang et al. PLoS One
- Apoptosis Is Essential for Neutrophil Functional Shutdown and Determines Tissue Damage in Experimental Pneumococcal Meningitis
- (2009) Uwe Koedel et al. PLoS Pathogens
- The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing
- (2008) Clifford D. Jones et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors
- (2008) Clifford D. Jones et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
- (2008) P. Sharma et al. CURRENT CANCER DRUG TARGETS
- The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation
- (2008) Sonja Baumli et al. EMBO JOURNAL
- Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)
- (2008) Janet S. Graham et al. EUROPEAN JOURNAL OF CANCER
- Meriolins (3-(Pyrimidin-4-yl)-7-azaindoles): Synthesis, Kinase Inhibitory Activity, Cellular Effects, and Structure of a CDK2/Cyclin A/Meriolin Complex†
- (2008) Aude Echalier et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification ofN-(4-Piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a Novel Cyclin Dependent Kinase Inhibitor Using Fragment-Based X-Ray Crystallography and Structure Based Drug Design†
- (2008) Paul G. Wyatt et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity†
- (2008) Steven Howard et al. JOURNAL OF MEDICINAL CHEMISTRY
- High-throughput kinase profiling as a platform for drug discovery
- (2008) David M. Goldstein et al. NATURE REVIEWS DRUG DISCOVERY
- Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology
- (2008) S WANG et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Structure-guided discovery of cyclin-dependent kinase inhibitors
- (2007) Thierry O. Fischmann et al. BIOPOLYMERS
- CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases
- (2007) S.H. Obligado et al. KIDNEY INTERNATIONAL
- CDK inhibitors in cancer therapy: what is next?
- (2007) Marcos Malumbres et al. TRENDS IN PHARMACOLOGICAL SCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now